|
Anikin D.A., Solovieva I.A., Demko I.V., Sobko E.A., Gordeeva N.V., Kraposhina A.Yu.
Peculiarities of the association of bronchial asthma with obesity depending on the time of asthma debut and the possibilities of cardiovascular risk prediction in this group of patients
|
№10 / 2022
|
|
Larina V.N., Fedorova E.V., Sayno O.V., Mironova T.N., Orlov D.A.
The incidence of abdominal obesity and its association with risk factors for cardiovascular disease in middle-aged people
|
№8 / 2022
|
|
Mazurov V.I., Gaydukova I.Z., Tsinzerling A.Yu., Bashkinov R.A., Inamova O.V., Petrova M.S.
The effect of asymptomatic hyperuricemia on the frequency and structure of comorbidity patients with rheumatoid arthritis
|
№6 / 2022
|
|
Derevyanchenko M.V., Fedotov V.V., Shaposhnikova M.Yu., Kolodin S.V.
Assessment of the risk of developing cardiovascular diseases on the SCORE-2 and SCORE 2-OP scale in patients with arterial hypertension using software tools
|
№3 / 2022
|
|
Demidova T.Yu., Mkrtumyan A.M.
Review of current opportunities in cardiovascular risks management in patients with type 2 diabetes mellitus
|
№9 / 2021
|
|
Demidova T.Yu., Alekseeva Ya.G.
The place of sodium glucose co-transporter-2 inhibitors in the treatment of type 2 diabetes mellitus and its complications from the evidence-based medicine viewpoint
|
№8 / 2020
|
|
Vershinina M.V., Nechaeva G.I., Gudilin V.A.
Relative cardiovascular risk in young patients with connective tissue dysplasia
|
№6 / 2020
|
|
Murkamilov I.T., Aitbaev K.A., Fomin V.V., Murkamilova Zh.A., Rayimzhanov Z.R., Redjapova N.A., Yusupov F.A.
Braking progression of nephro- and cerebrovascular complications during atrial fibrillation: opportunities of rivaroxaban
|
№1 / 2020
|
|
Halimov Yu.Sh., Sergienko I.V., Kuzmich V.G.
Cardiovascular comorbidity in type 2 diabetes mellitus: potential of use of glucagon-like peptide type 1 receptor agonists
|
№6 / 2019
|
|
Ametov A.S., Rubtsov Yu.E., Saluhov V.V., Khalimov Yu.Sh., Agafonov P.V.
Elimination of adipose tissue dysfunction as a major factor in reducing cardiometabolic risks in obesity
|
№6 / 2019
|
|
Polyakova I.V., Borovkova N.Yu., Maslova T.I., Maksimova I.Yu., Zubova S.Yu., Solov’yanova E.N.
View of the vascular stiffness and cardiovascular risk in patients with chronic glomerulonephritis
|
№2 / 2019
|
|
I.I. Shaposhnik, I.I. Reznik
The use of statines in outpatient practice in high and very highrisk patients
|
№5 / 2017
|
Русский
